These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27864841)

  • 1. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
    Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
    J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting.
    Molina-Leyva A; Husein-Elahmed H; Naranjo-Sintes R; Ruiz-Carrascosa JC
    J Drugs Dermatol; 2014 Aug; 13(8):971-4. PubMed ID: 25116977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
    Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
    Elberdín L; Fernández-Torres R; Paradela S; Blanco E; Outeda M; Martín I; Fonseca E
    J Dermatolog Treat; 2020 Nov; 31(7):698-701. PubMed ID: 30961404
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
    van Vugt LJ; van den Reek JMPA; Hannink G; Coenen MJH; de Jong EMGJ
    JAMA Dermatol; 2019 Jun; 155(6):708-715. PubMed ID: 30994858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY; Chu TW; Cheng YP; Tsai TF
    PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and
    Kim SJ; Park MY; Pak K; Han J; Kim GW; Kim HS; Ko HC; Kim MB; Kim BS
    J Dermatolog Treat; 2018 Dec; 29(8):761-768. PubMed ID: 29658378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of ustekinumab for moderate-to-severe psoriasis: A 9-year real-life experience from a tertiary referral center in Turkey.
    Babuna Kobaner G; Polat Ekinci A; Kutlay A
    Dermatol Ther; 2021 Jul; 34(4):e15042. PubMed ID: 34161621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis.
    Raposo I; Bettencourt A; Leite L; Selores M; Torres T
    Acta Med Port; 2019 Mar; 32(3):214-218. PubMed ID: 30946793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real life experience with ustekinumab: The effectiveness of 45 mg on patients greater than 80 kg but lower than 100 kg.
    Koç Yıldırım S; Demirel Öğüt N; Erbağcı E; Hapa FA
    Dermatol Ther; 2022 Jun; 35(6):e15494. PubMed ID: 35384189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.
    Romero-Jimenez RM; Escudero-Vilaplana V; Baniandres Rodriguez O; García Martín E; Mateos Mayo A; Sanjurjo Saez M
    J Dermatolog Treat; 2018 Dec; 29(8):792-796. PubMed ID: 29676189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab in clinical practice: response depends on dose and previous treatment.
    Ruiz Salas V; Puig L; Alomar A
    J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):508-13. PubMed ID: 22077903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Association Study of Ustekinumab Response in Psoriasis.
    Connell WT; Hong J; Liao W
    Front Immunol; 2021; 12():815121. PubMed ID: 35154085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment.
    Beroukhim K; Danesh M; Nguyen C; Farahnik B; Levin E; Leon A; Koo J
    J Dermatolog Treat; 2016 Nov; 27(6):552-555. PubMed ID: 27052387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Mass Index, Disease Duration and Tumor Necrosis Factor Inhibitor History Predict Reduced Ustekinumab Response in Chinese Psoriasis Patients: A Real-World Study.
    Xu X; Qin G; Meng Z; Pei D
    Indian J Dermatol; 2021; 66(5):574. PubMed ID: 35068529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
    Savage L; Goodfield M; Horton L; Watad A; Hensor E; Emery P; Wakefield R; Wittmann M; McGonagle D
    Arthritis Rheumatol; 2019 Apr; 71(4):626-631. PubMed ID: 30468001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.